Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Insmed Inc INSM

Healthcare Biotechnology
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs... see more

Recent & Breaking News (NDAQ:INSM)

Insmed to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call on Friday, February 23, 2018

GlobeNewswire February 15, 2018

Insmed to Present at the Leerink Partners 7th Annual Global Healthcare Conference

GlobeNewswire February 7, 2018

Insmed Announces Closing of Public Offering

GlobeNewswire January 26, 2018

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire January 24, 2018

40 Biggest Movers From Yesterday

Benzinga.com  January 24, 2018

Insmed Announces Pricing of Public Offering of Convertible Senior Notes

GlobeNewswire January 23, 2018

Mid-Morning Market Update: Markets Mixed; Johnson & Johnson Beats Q4 Views

Benzinga.com  January 23, 2018

Insmed Announces Proposed Public Offering of Convertible Senior Notes

GlobeNewswire January 22, 2018

Insmed Announces Additional Data from ALIS (Amikacin Liposome Inhalation Suspension) Phase 3 Clinical Program for Adult Patients with Treatment Refractory NTM Lung Disease Caused by MAC and Reports Progress with Commercial Preparations

GlobeNewswire January 3, 2018

Insmed to Present at the Nasdaq 37th Annual Investor Conference

GlobeNewswire November 28, 2017

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire November 22, 2017

Insmed to Present at Two November Conferences

GlobeNewswire November 8, 2017

Insmed Reports Third Quarter 2017 Financial Results and Provides Business Update

GlobeNewswire November 2, 2017

Insmed Incorporated to Host Earnings Call

Accesswire November 2, 2017

Insmed to Host Third Quarter 2017 Financial Results Conference Call on Thursday, November 2, 2017

GlobeNewswire October 25, 2017

Stocks Under Scanner in the Biotech Space -- ImmunoGen, Incyte, Infinity Pharma, and Insmed

PR Newswire October 5, 2017

Insmed to Present at Two September Investor Conferences

GlobeNewswire September 19, 2017

Insmed Announces Closing of Public Offering

GlobeNewswire September 11, 2017

Watch These 8 Huge Call Purchases In Thursday Trade

Benzinga.com  September 7, 2017

Insmed Announces Pricing of Public Offering of Common Stock

GlobeNewswire September 6, 2017
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested